Gastrinoma of the stomach

International Journal of Gastrointestinal Cancer

Volumn 35, Issue 3, 2005, Pages 211-216

  Tartaglia, Andreas ^a   Vezzadini, Chiara ^a   Bianchini, Silvia ^a   Vezzadini, Paolo ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Gastric carcinoid; Gastrin; Gastrinoma; Somatostatin analogs

Indexed keywords

ANGIOPEPTIN; GASTRIN; PROTON PUMP INHIBITOR; SOMATOSTATIN DERIVATIVE; ANTINEOPLASTIC AGENT; CYCLOPEPTIDE; DRUG DERIVATIVE; SOMATOSTATIN;

ADULT; ARTICLE; BIOCHEMISTRY; CANCER SURGERY; CASE REPORT; CHOLELITHIASIS; CLINICAL FEATURE; CONVALESCENCE; DISEASE ASSOCIATION; DRUG RESPONSE; ENDOCRINE TUMOR; FOLLOW UP; GASTRIN BLOOD LEVEL; GASTRINOMA; HUMAN; HUMAN TISSUE; INCIDENCE; LIVER METASTASIS; LONG TERM CARE; MALE; MINIMAL RESIDUAL DISEASE; PEPTIC ULCER; PRIORITY JOURNAL; PROVOCATION TEST; STOMACH TUMOR; TREATMENT OUTCOME; TUMOR DIAGNOSIS; DIFFERENTIAL DIAGNOSIS; GASTRECTOMY; PATHOLOGY;

ADULT; ANTINEOPLASTIC AGENTS; DIAGNOSIS, DIFFERENTIAL; GASTRECTOMY; GASTRINOMA; HUMANS; MALE; PEPTIC ULCER; PEPTIDES, CYCLIC; SOMATOSTATIN; STOMACH NEOPLASMS;

EID: 23844525442     PISSN: 01694197     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Stabile BE, Morrow DJ, Passaro E Jr. The gastrinoma triangle: operative implications. Am J Surg 1984;147(1):25-31.
2. Wu PC, Alexander HR, Bartlett DL, et al. A prospective analysis of the frequency, location, and curability of ectopic (nonpancreaticoduodenal, nonnodal) gastrinoma. Surgery 1997;122(6):1176-1182.
3. Farley DR, van Heerden JA, Grant CS, Thompson GB. Extrapancreatic gastrinomas. Arch Surg 1994;129(5):506-511.
4. Rindi G, Bordi C, Rappel S, La Rosa S, Stolte M, Solcia E. Gastric carcinoids and neuroendocrine carcinomas: pathogenesis, pathology, and behavior. World J Surg 1996; 20(2):168-172.
5. McGuigan JE, Wolfe MM. Secretin injection test in the diagnosis of gastrinoma. Gastroenterology 1980;79:1324-1331.
6. Vezzadini C, Poggioli R, Casoni I, Vezzadini P. Use of calcium provocative test in the diagnosis of gastroenteropancreatic endocrine tumors. Panminerva Med 1996;38(4): 255-258.
7. Arnold WS, Fraker DL, Alexander HR, Weber HC, Norton JA, Jensen RT. Apparent lymph node primary gastrinoma. Surgery 1994;16:1123-1130.
8. Cocco AE, Conway SJ. Zollinger-Ellison syndrome associated with ovarian mucinous cystadenocarcinomas. N Engl J Med 1975;293:485-486.
9. Primrose JN, Maloney M, Wells M, Bulgin O, Johnston D. Gastrin-producing ovarian mucinous cystadenocarcinomas: a cause of Zollinger-Ellison syndrome. Surgery 1988;104:830-833.
10. Morgan DR, Wells M, MacDonald RC, Johnston D. Zollinger-Ellison syndrome due to a gastrin secreting ovarian mucinous cystadenoma: case report. Br J Obstet Gynaecol 1985;92:867-869.
11. Liu TH, Zhong SX, Chen YF, et al. Gastric gastrinoma. Chin Med J 1989;102:774-782.
12. Werbel GB, Nelson SP, Robinson PG, Anastasi J, Joehl RJ, Rege RV. A foregut carcinoid tumor causing Zollinger-Ellison syndrome. Arch Surg 1989;124:381-384.
13. Thompson NW, Vinik AI, Eckhauser FE, Strodel WE. Extrapancreatic gastrinomas. Surgery 1985;98:1113-1120.
14. Jensen RT, Gibril F, Termanini B. Definition of the role of the somatostatin receptor scintigraphy in gastrointestinal neuroendocrine tumor localization. Yale J Biol Med 1997;70:481-500.
15. Mignon M, Ruszniewski P, Haffar S, Rigaud D, Rene E, Bonfils S. Current approach to the management of tumoral process in patients with gastrinoma. World J Surg 1986; 10(4):703-710.
16. Chaudhry A, Öberg K, Wilander E. A study of biological behavior based on the expression of a proliferating antigen in neuroendocrine tumors of the digestive system. Tumour Biol 1992;13(1-2):27-35.
17. Arnold R, Trautmann ME, Creutzfeldt W, et al. Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumour. Gut 1996;3:430-438.
18. Di Bartlomeo M, Bajetta E, Buzzoni R, et al. Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by Italian Trials in Medical Oncology Group. Cancer 1996;77:402-408.
19. Saltz L, Trochanowsky B, Buckley M, et al. Octerotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors. Cancer 1993;72:244-248.
20. Harris AG, Redfern JS. Octreotide treatment of carcinoid syndrome: analysis of published dose-titration data. Aliment Pharmacol Ther 1995;9:387-384.
21. Imam H, Eriksson B, Lukinius A, et al. Induction of apoptosis in neuroendocrine tumors of the digestive system during treatment with somatostatin analogs. Acta Oncol 1997;36(6):607-614.